Session: MON 414-436-HPT Axis Biology & Action
Poster Board MON-431
Methods: The expression levels of five reported dysregulated miRNAs (miRNA-221, miRNA-222,miRNA-146b, miRNA-181 and miRNA-21) were examined by quantitative real time polymerase chain reaction (qRT-PCR) in 52 patients with PTC and 52 patients with benign thyroid nodules (BTN). BRAF mutation status was determined using DNA-sequencing method. The association between the expression of miRNAs with BRAF mutation and a variety of clinicopathogenetical data was analyzed.
Results: The expression levels of miRNA-221, miRNA-222,miRNA-146b, miRNA-181 and miRNA-21 were significantly increased in PTC when compared to BTN. All of these five miRNAs could be used to differentiate PTC from BTN, with miRNA-146b yielding the largest area under the receiver operator characteristic (ROC) curve of 0.952 with 90.4% sensitivity and 88.5% specificity. The BRAF mutation occurred more frequently in PTC cases with advanced TNM stage. Importantly, miRNA-221, miRNA-222, miRNA-146b and miRNA-181 expression levels were significantly higher in PTC patients with BRAF mutation. In addition, enhanced expression of miRNA-221 and miRNA-222 were associated with cervical lymph node metastasis and advanced TNM stage, while patients with larger tumors had increased expression of miRNA-221 and miR-181.
Conclusion: Our study showed a potential role of this distinct profile of miRNAs in differentiating PTC from BTN. BRAF mutation might regulate or interact with miRNA-221, miRNA-222 and miRNA 146b in the pathogenesis and progression of PTC.
Nothing to Disclose: SY, HX
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters